Epigral (EPIGRAL) Stock Overview
Manufactures and sells chlor-alkali and derivative products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
EPIGRAL Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Epigral Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,127.60 |
| 52 Week High | ₹2,114.00 |
| 52 Week Low | ₹807.00 |
| Beta | 0.18 |
| 1 Month Change | -9.09% |
| 3 Month Change | 33.33% |
| 1 Year Change | -34.87% |
| 3 Year Change | -0.78% |
| 5 Year Change | n/a |
| Change since IPO | 177.43% |
Recent News & Updates
Narrative Update • Jun 07
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts have kept Epigral's fair value estimate steady at ₹2,000. They point to broadly unchanged assumptions on discount rate, revenue growth, profit margin and future P/E as the basis for maintaining their price target view.Narrative Update • May 24
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts are keeping the fair value estimate for Epigral steady at ₹2,000, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers behind the updated price target framework. What's in the News Board meeting scheduled for May 2, 2026, to review audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026, and to consider the statutory auditors' report (company filing).Recent updates
Narrative Update • Jun 07
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts have kept Epigral's fair value estimate steady at ₹2,000. They point to broadly unchanged assumptions on discount rate, revenue growth, profit margin and future P/E as the basis for maintaining their price target view.Narrative Update • May 24
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts are keeping the fair value estimate for Epigral steady at ₹2,000, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers behind the updated price target framework. What's in the News Board meeting scheduled for May 2, 2026, to review audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026, and to consider the statutory auditors' report (company filing).Analysis Article • May 08
Epigral Limited's (NSE:EPIGRAL) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts
Celebrations may be in order for Epigral Limited ( NSE:EPIGRAL ) shareholders, with the covering analyst delivering a...Narrative Update • Apr 21
EPIGRAL: Steady ₹2,000 View Ahead Of 2026 Postal Ballot Outcome
Epigral's analyst fair value estimate is maintained at ₹2,000, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, as analysts fine tune their model inputs rather than changing their core view on the stock. What's in the News Epigral has scheduled a Special or Extraordinary Shareholders Meeting on May 19, 2026, to be conducted via postal ballot in India (Key Developments).Narrative Update • Apr 06
EPIGRAL: Steady ₹2,000 View Will Await Q3 Board Outcome
Analysts now keep Epigral's fair value estimate broadly unchanged at about ₹2,000 per share, with only minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions. This signals a largely steady view on the stock's valuation drivers.Narrative Update • Mar 23
EPIGRAL: Steady ₹2,000 Outlook Will Anticipate Q3 Board Meeting Outcome
Analysts have kept Epigral's fair value estimate steady at ₹2,000, with only minor tweaks to the discount rate, revenue growth, profit margin assumptions and future P/E supporting an unchanged price target. What's in the News A board meeting is scheduled on January 30, 2026 to consider the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report.Narrative Update • Mar 08
EPIGRAL: Steady ₹2,000 Fair Value Will Anticipate Q3 Board Review Outcome
Analysts have kept Epigral’s fair value estimate steady at ₹2,000, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects fine tuning of their models rather than a material change in conviction.Narrative Update • Feb 21
EPIGRAL: Reaffirmed ₹2,000 Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000. A slightly lower assumed future P/E and a marginally higher discount rate together support this unchanged price target.Narrative Update • Feb 07
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts now see fair value for Epigral at ₹2,000.00 per share, with the unchanged target based on updated assumptions on discount rate, revenue growth, profit margin and future P/E that together reflect a recalibration of their long term earnings and valuation framework. What's in the News A board meeting is scheduled on January 30, 2026 to consider unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report from statutory auditors (company filing).Narrative Update • Jan 24
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000 after updating their assumptions for discount rate, revenue growth, profit margin and future P/E. These revisions support a recalibrated price target narrative rather than a change in the overall valuation direction.Narrative Update • Jan 09
EPIGRAL: New CFO Appointment Is Expected To Strengthen Future Financial Governance
Analysts have cut their price target on Epigral from ₹2,600 to ₹2,000, citing updated assumptions that combine slightly higher revenue growth and profit margins with a lower future P/E multiple. What's in the News Epigral appointed Mr. Rakesh Agrawal as Chief Financial Officer and Key Managerial Personnel, effective 10 November 2025, following a board decision based on the Nomination and Remuneration Committee's recommendation (Key Developments).Analysis Article • Dec 26
Returns On Capital At Epigral (NSE:EPIGRAL) Have Hit The Brakes
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Analysis Article • Nov 16
Downgrade: What You Need To Know About The Latest Epigral Limited (NSE:EPIGRAL) Forecasts
Market forces rained on the parade of Epigral Limited ( NSE:EPIGRAL ) shareholders today, when the covering analyst...Analysis Article • Nov 13
Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models
Epigral Limited ( NSE:EPIGRAL ) shareholders are probably feeling a little disappointed, since its shares fell 9.0% to...Analysis Article • Nov 11
If EPS Growth Is Important To You, Epigral (NSE:EPIGRAL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Sep 28
Epigral (NSE:EPIGRAL) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Aug 06
Capacity Expansion And Green Energy Will Unlock Global Opportunities
The increase in Epigral’s consensus analyst price target to ₹2600 primarily reflects higher anticipated future earnings multiples, as indicated by the rise in future P/E, while the discount rate remains stable. What's in the News Upcoming board meeting to consider un-audited Q1 FY26 results and review fund-raising proposals via debt instruments.Analysis Article • Aug 06
Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next
NSEI:EPIGRAL 1 Year Share Price vs Fair Value Explore Epigral's Fair Values from the Community and select yours As you...Analysis Article • Jul 30
Epigral Limited (NSE:EPIGRAL) Might Not Be As Mispriced As It Looks
With a price-to-earnings (or "P/E") ratio of 23.6x Epigral Limited ( NSE:EPIGRAL ) may be sending bullish signals at...Analysis Article • Jun 02
Investors Should Be Encouraged By Epigral's (NSE:EPIGRAL) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Analysis Article • Apr 03
Subdued Growth No Barrier To Epigral Limited (NSE:EPIGRAL) With Shares Advancing 25%
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...Analysis Article • Feb 28
Calculating The Fair Value Of Epigral Limited (NSE:EPIGRAL)
Key Insights Epigral's estimated fair value is ₹1,644 based on 2 Stage Free Cash Flow to Equity With ₹1,630 share...
New Narrative • Jan 16
Doubling CPVC And ECH Production Will Strengthen Future Prospects
Epigral is expanding production capacity and focusing on high-margin value-added products to enhance earnings and future growth.Analysis Article • Dec 18
Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Jul 04
Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...Analysis Article • Apr 19
Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump
The Epigral Limited ( NSE:EPIGRAL ) share price has done very well over the last month, posting an excellent gain of...Analysis Article • Feb 23
Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward
Despite an already strong run, Epigral Limited ( NSE:EPIGRAL ) shares have been powering on, with a gain of 28% in the...Analysis Article • Feb 21
Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...Analysis Article • Apr 05
Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Analysis Article • Sep 28
With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Shareholder Returns
| EPIGRAL | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | 1.1% | 2.6% | 2.8% |
| 1Y | -34.9% | -0.4% | 0.9% |
Return vs Industry: EPIGRAL underperformed the Indian Chemicals industry which returned -0.5% over the past year.
Return vs Market: EPIGRAL underperformed the Indian Market which returned 2.1% over the past year.
Price Volatility
| EPIGRAL volatility | |
|---|---|
| EPIGRAL Average Weekly Movement | 7.2% |
| Chemicals Industry Average Movement | 7.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.6% |
Stable Share Price: EPIGRAL has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: EPIGRAL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,135 | Kaushal Soparkar | www.epigral.com |
Epigral Limited manufactures and sells chlor-alkali and derivative products in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resin, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda and potash, chlorine, hydrogen, chloromethanes, captive power plant (CPP), and chlorotoluene value chain, as well as operates wind-solar hybrid power plant. Its products are used in CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes.
Epigral Limited Fundamentals Summary
| EPIGRAL fundamental statistics | |
|---|---|
| Market cap | ₹48.65b |
| Earnings (TTM) | ₹3.32b |
| Revenue (TTM) | ₹25.27b |
14.7x
P/E Ratio1.9x
P/S RatioIs EPIGRAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EPIGRAL income statement (TTM) | |
|---|---|
| Revenue | ₹25.27b |
| Cost of Revenue | ₹15.75b |
| Gross Profit | ₹9.52b |
| Other Expenses | ₹6.20b |
| Earnings | ₹3.32b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 76.95 |
| Gross Margin | 37.69% |
| Net Profit Margin | 13.14% |
| Debt/Equity Ratio | 25.3% |
How did EPIGRAL perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield6%
Payout RatioDoes EPIGRAL pay a reliable dividends?
See EPIGRAL dividend history and benchmarks| Epigral dividend dates | |
|---|---|
| Ex Dividend Date | Jun 01 2026 |
| Dividend Pay Date | Jul 08 2026 |
| Days until Ex dividend | 20 days |
| Days until Dividend pay date | 17 days |
Does EPIGRAL pay a reliable dividends?
See EPIGRAL dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/19 14:57 |
| End of Day Share Price | 2026/06/19 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Epigral Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BP Wealth Management Private Limited |
| null null | Emkay Global Financial Services Ltd. |
| Meet Vora | Emkay Global Financial Services Ltd. |